These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 1858696)

  • 1. Fluoxetine's effect on weight loss in obese subjects.
    Darga LL; Carroll-Michals L; Botsford SJ; Lucas CP
    Am J Clin Nutr; 1991 Aug; 54(2):321-5. PubMed ID: 1858696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fluoxetine: a randomized clinical trial in the treatment of obesity.
    Goldstein DJ; Rampey AH; Enas GG; Potvin JH; Fludzinski LA; Levine LR
    Int J Obes Relat Metab Disord; 1994 Mar; 18(3):129-35. PubMed ID: 8186809
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fluoxetine: a randomized clinical trial in the maintenance of weight loss.
    Goldstein DJ; Rampey AH; Dornseif BE; Levine LR; Potvin JH; Fludzinski LA
    Obes Res; 1993 Mar; 1(2):92-8. PubMed ID: 16350565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical studies with fluoxetine in obesity.
    Wise SD
    Am J Clin Nutr; 1992 Jan; 55(1 Suppl):181S-184S. PubMed ID: 1728831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study.
    Muls E; Kolanowski J; Scheen A; Van Gaal L;
    Int J Obes Relat Metab Disord; 2001 Nov; 25(11):1713-21. PubMed ID: 11753595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An assessment of the thermogenic effects of fluoxetine in obese subjects.
    Stinson JC; Murphy CM; Andrews JF; Tomkin GH
    Int J Obes Relat Metab Disord; 1992 May; 16(5):391-5. PubMed ID: 1319975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluoxetine treatment of the obese diabetic.
    Gray DS; Fujioka K; Devine W; Bray GA
    Int J Obes Relat Metab Disord; 1992 Mar; 16(3):193-8. PubMed ID: 1317828
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A double-blind, placebo-controlled trial of fluoxetine plus behavior modification in the treatment of obese binge-eaters and non-binge-eaters.
    Marcus MD; Wing RR; Ewing L; Kern E; McDermott M; Gooding W
    Am J Psychiatry; 1990 Jul; 147(7):876-81. PubMed ID: 2192563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An open-label pilot study of the combination therapy of metformin and fluoxetine for weight reduction.
    Dastjerdi MS; Kazemi F; Najafian A; Mohammady M; Aminorroaya A; Amini M
    Int J Obes (Lond); 2007 Apr; 31(4):713-7. PubMed ID: 16969361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of fluoxetine, a selective serotonin-uptake inhibitor, in the treatment of obesity: a dose-response study (with a commentary by Michael Weintraub).
    Levine LR; Enas GG; Thompson WL; Byyny RL; Dauer AD; Kirby RW; Kreindler TG; Levy B; Lucas CP; McIlwain HH
    Int J Obes; 1989; 13(5):635-45. PubMed ID: 2583918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of fluoxetine and placebo in the treatment of obesity.
    Fernández-Soto ML; González-Jiménez A; Barredo-Acedo F; Luna del Castillo JD; Escobar-Jiménez F
    Ann Nutr Metab; 1995; 39(3):159-63. PubMed ID: 7486842
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Zonisamide for weight loss in obese adults: a randomized controlled trial.
    Gadde KM; Franciscy DM; Wagner HR; Krishnan KR
    JAMA; 2003 Apr; 289(14):1820-5. PubMed ID: 12684361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of fluoxetine on body weight, body composition and visceral fat accumulation.
    Visser M; Seidell JC; Koppeschaar HP; Smits P
    Int J Obes Relat Metab Disord; 1993 May; 17(5):247-53. PubMed ID: 8389333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized double-blind clinical trial of fluoxetine in obese diabetics.
    Gray DS; Fujioka K; Devine W; Bray GA
    Int J Obes Relat Metab Disord; 1992 Dec; 16 Suppl 4():S67-72. PubMed ID: 1338389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial.
    Astrup A; Madsbad S; Breum L; Jensen TJ; Kroustrup JP; Larsen TM
    Lancet; 2008 Nov; 372(9653):1906-1913. PubMed ID: 18950853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluoxetine increases resting energy expenditure and basal body temperature in humans.
    Bross R; Hoffer LJ
    Am J Clin Nutr; 1995 May; 61(5):1020-5. PubMed ID: 7733022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analyses of suicidality in double-blind, placebo-controlled trials of pharmacotherapy for weight reduction.
    Goldstein DJ; Rampey AH; Potvin JH; Masica DN; Beasley CM
    J Clin Psychiatry; 1993 Aug; 54(8):309-16. PubMed ID: 8253699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of sibutramine in obese mexican adolescents: a 6-month, randomized, double-blind, placebo-controlled, parallel-group trial.
    García-Morales LM; Berber A; Macias-Lara CC; Lucio-Ortiz C; Del-Rio-Navarro BE; Dorantes-Alvárez LM
    Clin Ther; 2006 May; 28(5):770-82. PubMed ID: 16861099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial.
    Pi-Sunyer FX; Aronne LJ; Heshmati HM; Devin J; Rosenstock J;
    JAMA; 2006 Feb; 295(7):761-75. PubMed ID: 16478899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cognitive behavioral therapy and fluoxetine as adjuncts to group behavioral therapy for binge eating disorder.
    Devlin MJ; Goldfein JA; Petkova E; Jiang H; Raizman PS; Wolk S; Mayer L; Carino J; Bellace D; Kamenetz C; Dobrow I; Walsh BT
    Obes Res; 2005 Jun; 13(6):1077-88. PubMed ID: 15976151
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.